Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit.among patients with cardiovascular disease but is also not significantly safer in terms of bleeding risk, results of a post hoc analysis of data from a randomized clinical trial suggest.
Of participants enrolled in ADAPTABLE, 10,678 reported the aspirin formulation used; the median age of this sample was 68.0 years, 68.2% were men, and 84.0% were White.In the enteric-coated aspirin group, the cumulative incidence of death, MI or stroke was 6.6% with the 81-mg dose and 7.
Only 70.1% of participants reported aspirin formulation at baseline, which they could have switched during the study, and unknown confounders may have affected choice of aspirin formulation. Use of enteric-coated aspirin was not part of the randomization stratification, so the data must be treated as if from an observational study. Enrollment of women and minority groups was relatively low, so generalizability of the results remains questionable.
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see ourComments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see ourHelp us make reference on Medscape the best clinical resource possible.
Please use this form to submit your questions or comments on how to make this article more useful to clinicians.use this form to submit personal or patient medical information or to report adverse drug events. You are encouraged to report adverse drug event information to the FDA.